GLP-1 Risks for Seniors: What Changes After 65
By WPG Research Team · Last verified
The biggest GLP-1 risks for seniors are dehydration that can hurt the kidneys, dizziness and falls from low blood pressure, hip and pelvis fractures after 75, muscle loss, and eating too little. Most are manageable with clinician oversight. Don't use a GLP-1 if you or a family member has had medullary thyroid cancer (MTC), or if you have MEN 2.
Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers.
| Risk | What the FDA label or FDA says | Why it matters more after 65 | What to watch for |
|---|---|---|---|
| Dehydration and kidney injury | Acute kidney injury has been reported, sometimes needing dialysis, mostly after nausea, vomiting or diarrhea | Wegovy's label says kidney problems were more common in people who already had kidney disease | Dark urine, peeing less, dizziness, confusion |
| Low blood pressure and fainting | Wegovy: low blood pressure 1.3% vs 0.4% on placebo; fainting 0.8% vs 0.2% | More common in people taking blood pressure medicine | Lightheaded when you stand up |
| Hip and pelvis fractures | In Wegovy's heart trial, 2.4% of people 75 and older had these fractures vs 0.6% on placebo | Seen in the 75+ group, not in younger adults | Any fall, new hip or groin pain |
| Muscle loss | Lean mass fell about 10% in semaglutide and tirzepatide body-scan studies | Muscle is harder to rebuild with age | Weaker grip, trouble with stairs or getting up |
| Eating too little | Nausea hit 44% on Wegovy vs 16% on placebo | Less food can mean too little protein and fluid | Skipping meals, losing weight too fast |
| Low blood sugar | Risk rises with insulin or sulfonylureas | Many older adults with diabetes take these | Shaky, sweaty, confused |
| Pill interactions | GLP-1s slow the stomach; the Wegovy tablet raised levothyroxine levels 33% | More daily pills means more to check | Changes in how other medicines work |
| Surgery and anesthesia | Rare reports of food entering the lungs under anesthesia | Older adults have more procedures | Tell every surgeon and dentist |
| Sudden vision loss (NAION) | FDA ordered a new warning on all GLP-1s on November 9, 2026 | Risk factors like diabetes, high blood pressure and sleep apnea are common with age | Sudden, painless vision loss in one eye |
| Pancreas and gallbladder | Rare pancreatitis; more gallstones and gallbladder swelling than placebo | Rapid weight loss raises gallstone risk at any age | Severe belly pain, pain into the back |
Bottom line: Age alone doesn't rule out a GLP-1. There's no upper age limit on the Wegovy, Zepbound or Foundayo labels, and none of them found an overall difference in how well the medicine works after 65. The catch is that few people over 75 were studied, and the risks that hurt seniors most (dehydration, falls, fractures and muscle loss) are the ones that build quietly. A clinician should review your kidney function, blood pressure and full medicine list before you start, and check in during every dose increase.
Why GLP-1 risks look different for seniors
GLP-1 medicines were tested mostly in middle-aged adults. That matters because the people most likely to have side effects, those over 75, are the people the trials studied least.
Each medicine's FDA label lists how many older adults were in its main trials:
| Medicine | Form | Ages 65 and older | Ages 75 and older | What the label says about age |
|---|---|---|---|---|
| Wegovy injection (semaglutide) | Weekly shot | 9% (ages 65 to 74) in weight-loss trials | 1% | No overall difference in effectiveness after 65 |
| Wegovy injection, heart outcomes trial | Weekly shot | 30% (ages 65 to 75) | 8% (703 people) | People 75+ had more hip and pelvis fractures on Wegovy, and more serious side effects overall in both groups |
| Wegovy tablets (semaglutide) | Daily pill | 8% (ages 65 to 74) | 2% | Same label as the injection |
| Zepbound (tirzepatide) | Weekly shot | 9% | 0.5% (13 people) | No overall differences in safety or effectiveness after 65 |
| Foundayo (orforglipron) | Daily pill | 13% | 1% (33 people) | No overall differences in safety or effectiveness after 65 |
The largest senior safety data set is Wegovy's heart outcomes trial, which included 703 people 75 and older on the drug. That trial is also where the fracture signal showed up. Zepbound's weight-loss trials included only 13 people 75 or older on the drug, so "no difference" means "no difference seen in a small group," not proof of safety at 80.
Age also changes the body in ways that make common side effects hit harder. A senior who loses fluid from vomiting, takes a water pill and a blood pressure pill, and eats less has less room for error than a 40-year-old with the same nausea. That's why the rest of this page goes risk by risk.
Risk 1: Dehydration and kidney injury
Dehydration from nausea, vomiting or diarrhea can cause acute kidney injury in people taking GLP-1 medicines. Both the Wegovy and Zepbound labels warn about this, and both report cases that needed dialysis after the drugs reached the market.
What the labels report:
- In Wegovy's weight-loss trials, acute kidney injury happened at 0.4 cases per 100 patient-years vs 0.2 on placebo. Kidney problems were more common in people with a history of kidney disease, and more common while the dose was going up.
- In Zepbound's weight-loss trials, acute kidney injury was reported in 0.5% of people vs 0.2% on placebo.
- Both labels tell clinicians to check kidney function in people who have side effects that could dry them out, especially when starting or raising the dose.
Zepbound's label says no dose change is needed for kidney disease. That doesn't remove the dehydration risk. It means the drug level itself isn't affected by kidney function.
What makes it worse after 65: many seniors take diuretics (water pills) or blood pressure medicines, which leaves less room for fluid loss. If you're vomiting or have diarrhea for more than a day, call your prescriber. Our GLP-1 dehydration symptoms guide and GLP-1 kidney problems guide cover the warning signs in more detail.
Risk 2: Dizziness, low blood pressure and falls
Low blood pressure and fainting happen more often on GLP-1s, and they happen most in people already taking blood pressure medicine. For a senior, a fainting spell can mean a fall, and a fall can mean a broken hip.
| Medicine | Low blood pressure on the drug | On placebo | Extra detail from the label |
|---|---|---|---|
| Wegovy | 1.3% | 0.4% | Fainting 0.8% vs 0.2%; more common with blood pressure medicine |
| Zepbound | 1.6% | 0.1% | 2.2% in people on blood pressure medicine vs 1.2% in people not on it |
| Foundayo | 2% | 0.5% | 4% in people on blood pressure medicine vs 1% in people not on it |
Dizziness was also reported by 8% of people on Wegovy 2.4 mg vs 4% on placebo.
As you lose weight, your blood pressure often drops, and some people end up needing less blood pressure medicine. The danger is when the dose of your blood pressure medicine stays the same while your body needs less. Ask your clinician how often to check your blood pressure at home in the first months, and what number should prompt a call. If you get lightheaded when you stand up, sit back down and tell your prescriber the same day. We cover blood pressure medicine questions in our guide to GLP-1s and high blood pressure.
Risk 3: Hip and pelvis fractures after 75
In Wegovy's heart outcomes trial, people 75 and older had about four times the rate of hip and pelvis fractures on Wegovy compared with placebo: 2.4% (17 of 703) vs 0.6% (4 of 663). Women in the same trial also had more of these fractures: 1% vs 0.2%.
This is the clearest age-specific safety finding on any GLP-1 label, and it's printed in Wegovy's geriatric use section. The label doesn't say why it happened. Falls from dizziness, bone loss during weight loss, and muscle loss are all possible reasons, and they can stack.
What this means in practice:
- If you're 75 or older, or you already have osteoporosis or a history of falls, bone health should be part of the conversation before you start.
- Ask whether a bone density scan makes sense for you, and whether your calcium and vitamin D intake are enough.
- Fall-proof the basics at home: lighting, rugs, grab bars, and getting up slowly.
The Zepbound and Foundayo labels don't report a similar fracture finding, but their trials included far fewer people over 75, so the absence of a signal isn't the same as proof of no risk.
Risk 4: Losing muscle along with fat
When you lose weight on a GLP-1, part of what you lose is lean mass, which includes muscle. Both labels say fat loss is greater than lean loss, and the body-scan studies give the numbers:
| Study | Weight lost | Fat mass change | Lean mass change | People scanned |
|---|---|---|---|---|
| STEP 1, semaglutide 2.4 mg, 68 weeks | About 15% | Down 19.3% | Down 9.7% | 140 |
| SURMOUNT-1, tirzepatide, 72 weeks | About 21% | Down 33.9% | Down 10.9% | 160 |
In SURMOUNT-1, about 75% of the weight lost was fat and 25% was lean mass, and the study's authors reported that split held across most subgroups they checked, including groups by sex, age and amount of weight lost. In STEP 1, lean mass made up a larger share of the body afterward because fat fell faster.
That's still a senior risk. Lean mass on a body scan includes water and organs as well as muscle, so these studies don't measure strength directly. But many older adults are already losing muscle with age, and losing about a tenth of lean mass on top of that can make stairs, chairs and balance harder. That ties straight back to the fall and fracture risks above.
What helps: enough protein at every meal and regular strength training, ideally planned with your clinician or a physical therapist. Our guide to preventing muscle loss on GLP-1s has a full plan. Signs to report: a weaker grip, trouble getting out of a chair, or feeling unsteady.
Risk 5: Eating too little
GLP-1s work by making you less hungry, and that can go too far for an older adult. Nausea, vomiting, diarrhea and constipation are the most common side effects. From Wegovy's label (2.4 mg weekly shot vs placebo):
| Side effect | Wegovy 2.4 mg | Placebo |
|---|---|---|
| Nausea | 44% | 16% |
| Diarrhea | 30% | 16% |
| Vomiting | 24% | 6% |
| Constipation | 24% | 11% |
| Dizziness | 8% | 4% |
In those trials, 6.8% of people on Wegovy stopped because of side effects vs 3.2% on placebo. Side effects are usually worst when starting and after each dose increase.
For seniors, the worry isn't the nausea itself. It's the knock-on effects: skipping meals means too little protein (more muscle loss), too little fluid (kidney risk), and fast weight loss (gallstone risk). If you're losing weight faster than your clinician expected, or you're regularly eating only one meal a day, that's worth a call. Our guide to what to eat with GLP-1 nausea has practical food ideas.
Severe stomach side effects are a separate warning on the Wegovy, Zepbound and Foundayo labels. They were reported in 4.1% of people on Wegovy injection vs 0.9% on placebo, and in 1.7% to 3.1% on Zepbound (by dose) vs 1% on placebo. After approval, Wegovy's label also lists reports of ileus (a stalled gut), intestinal blockage and severe constipation, including fecal impaction. None of these medicines is recommended for people with severe gastroparesis.
Risk 6: Low blood sugar if you take insulin or a sulfonylurea
GLP-1s rarely cause low blood sugar on their own, but the risk rises sharply when they're combined with insulin or a sulfonylurea such as glipizide, glyburide or glimepiride. Both the Wegovy and Zepbound labels say the dose of those medicines may need to come down when a GLP-1 starts.
In Zepbound's trial in people with type 2 diabetes, low blood sugar (below 54 mg/dL) was reported in 4.2% of people on Zepbound vs 1.3% on placebo.
Low blood sugar is more dangerous for older adults because it can look like confusion or weakness, and it can cause falls. If you have diabetes, your clinician should check your blood sugar before you start and during treatment. See our guide to GLP-1s with insulin and sulfonylureas.
Risk 7: Interactions with the pills you already take
GLP-1s slow how fast your stomach empties, which can change how your body absorbs other pills. That matters more when you take several medicines a day.
What the labels say:
- Levothyroxine (thyroid medicine): in a study with the semaglutide tablet, levothyroxine levels rose 33%. If you take thyroid medicine, ask about checking your thyroid levels after starting.
- Medicines with a narrow safe range: Wegovy's label tells clinicians to consider extra monitoring for oral medicines where small changes in blood level matter.
- Blood pressure medicines: low blood pressure was more common in people taking them (see Risk 2).
- Insulin and sulfonylureas: higher low-blood-sugar risk (see Risk 6).
- Other GLP-1s: Wegovy's label says not to combine it with other semaglutide products or any other GLP-1.
The pill form matters too. Wegovy tablets must be taken on an empty stomach in the morning with no more than 4 ounces of water, and you have to wait at least 30 minutes before eating, drinking or taking other pills. For a senior who takes a handful of morning pills, including levothyroxine, which has its own empty-stomach rule, that schedule can be hard to manage. Foundayo, the other GLP-1 pill, is taken once a day with or without food.
Bring a full medicine list, including over-the-counter pills and supplements, to your first visit. A good prescriber will ask for it.
Risk 8: Surgery, colonoscopy and anesthesia
Because GLP-1s slow the stomach, food can still be there during anesthesia, and there have been rare reports of it entering the lungs (pulmonary aspiration). The Wegovy, Zepbound and Foundayo labels all carry this warning.
The American Society of Anesthesiologists and four other medical groups issued joint guidance in October 2024. It says most patients can keep taking their GLP-1 before elective surgery. People at higher risk of a full stomach (those still raising their dose, those with stomach symptoms, or those on higher doses) may be asked to follow a liquid diet for 24 hours beforehand. Elective surgery may be postponed until the dose-raising phase is over and stomach symptoms have settled.
What to do: tell every surgeon, anesthesiologist, dentist and endoscopy team that you take a GLP-1, and follow their instructions. Don't stop on your own. Our guide to GLP-1s before surgery explains the timing questions to ask.
Risk 9: Sudden vision loss and eye problems
On November 9, 2026, the FDA announced it is requiring every GLP-1 medicine, including Wegovy, Ozempic, Zepbound, Mounjaro and Foundayo, to add a warning about NAION, a rare condition where blood flow to the optic nerve drops and vision is suddenly lost in one eye, sometimes permanently.
What the FDA found:
- Across 126 clinical trials, NAION happened at 6.4 cases per 100,000 person-years on a GLP-1 vs 3.8 on a comparison treatment.
- In adults over 50 in the general population, NAION occurs in about 2.3 to 10.2 people per 100,000 per year.
- Risk factors include smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. Many of those are common in older adults.
Europe's medicines regulator reached a similar conclusion for semaglutide in June 2025, calling NAION a very rare side effect affecting up to 1 in 10,000 people.
The symptom to act on: sudden, painless vision loss in one eye, often noticed on waking, or new blind spots, blurry patches or faded colors. Call your doctor right away. If you've had NAION before, discuss whether a GLP-1 is right for you before starting.
A second eye risk applies to people with type 2 diabetes. In a two-year semaglutide trial, diabetic retinopathy complications happened in 3% of people vs 1.8% on placebo, and the gap was bigger in people who already had retinopathy (8.2% vs 5.2%). If you have diabetic eye disease, keep your regular eye exams. See our guide to GLP-1 vision changes.
Risk 10: Pancreatitis, gallbladder problems and other label warnings
Pancreatitis is rare on GLP-1s, but it can be serious, and gallbladder problems are more common than on placebo.
| Problem | Wegovy | Zepbound | Placebo comparison |
|---|---|---|---|
| Acute pancreatitis | 0.2 cases per 100 patient-years | 0.2% | Wegovy placebo under 0.1 per 100 patient-years; Zepbound placebo 0.2% |
| Gallstones | 1.6% | 1.1% | 0.7% (Wegovy trials); 1% (Zepbound trials) |
| Gallbladder inflammation | 0.6% | 0.7% | 0.2% in both |
Rapid weight loss raises gallstone risk on its own, but Wegovy's label says gallbladder problems were still more common on the drug after accounting for weight loss. Severe pain in the upper belly, especially pain that spreads to the back, needs medical care the same day. See our guides to pancreatitis warning signs and gallbladder symptoms.
Other warnings on the labels:
- Heart rate: resting heart rate rose 1 to 4 beats per minute on average with Wegovy, and 26% of people had a rise of 20 or more at some visit vs 16% on placebo. Tell your clinician about a racing heart at rest.
- Allergic reactions: serious reactions such as swelling of the face or throat are rare but possible. Get emergency help if they happen.
- Thyroid tumors: the Wegovy, Zepbound and Foundayo labels carry a boxed warning based on rodent studies. Don't use a GLP-1 if you or a family member has had medullary thyroid cancer (MTC), or if you have MEN 2. Report a lump in your neck, trouble swallowing or lasting hoarseness.
Is there a safest GLP-1 for seniors?
No single GLP-1 is safest for every older adult. The safest choice is an FDA-approved medicine matched to your other conditions, at a dose raised slowly, with a clinician checking in. The labels do differ in ways that matter for seniors:
- Wegovy injection has the most data in people 75 and older, from a heart trial where it also lowered the risk of heart attack, stroke and heart-related death in people with heart disease. That same trial is where the fracture finding came from.
- Zepbound has no kidney dose adjustment and is also approved for moderate to severe obstructive sleep apnea in adults with obesity, but its weight trials included very few people over 75.
- The two pills differ in daily routine: Wegovy tablets need an empty stomach and a 30-minute wait, while Foundayo can be taken with or without food.
Compounded GLP-1s are a different category with extra risks (next section). For a side-by-side of medicines and programs for older adults, see our best GLP-1 for seniors guide.
Compounded GLP-1s carry extra risks for older adults
Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before they're sold. The FDA has flagged problems that are especially relevant to seniors:
- Dosing mistakes: the FDA has received reports of adverse events, some requiring hospitalization, tied to people measuring the wrong dose from compounded vials, and in some cases to clinicians miscalculating doses. Drawing up a dose with a syringe is harder with weaker eyesight or stiff hands.
- Doses beyond the label: the FDA has also received reports tied to compounded doses higher than, or increased faster than, the FDA-approved schedule.
- Underreporting: as of May 31, 2026, the FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide. Because most compounding pharmacies aren't required to report adverse events, the FDA says the true number is likely higher.
None of the label safety data on this page comes from compounded products. If you're weighing a compounded option, our guide to whether compounded semaglutide is safe covers the questions to ask.
Who should not take a GLP-1, or should talk to a doctor first
Don't take a GLP-1 if:
- You or a family member has had medullary thyroid cancer (MTC), or you have MEN 2.
- You've had a serious allergic reaction to the medicine or its ingredients.
The labels say these medicines are not recommended if:
- You have severe gastroparesis (a very slow stomach).
Talk with your doctor in person first if you:
- Have had pancreatitis.
- Have moderate or severe kidney disease, or get dehydrated easily.
- Take insulin or a sulfonylurea.
- Have diabetic eye disease, or have had NAION.
- Are 75 or older with osteoporosis or a history of falls.
- Are losing weight without trying, have a poor appetite, or are frail.
- Have surgery or a procedure coming up.
For the full list, see our GLP-1 contraindications guide.
What's normal, when to call, and when to get help now
| What you notice | What it usually means | What to do |
|---|---|---|
| Mild nausea, fullness or less appetite in the first weeks or after a dose increase | Common, expected side effect | Eat smaller meals, drink fluids, mention it at your next check-in |
| Constipation for a few days | Common | Fluids and fiber; call if it lasts or you have belly swelling |
| Vomiting or diarrhea for more than a day | Dehydration risk | Call your prescriber the same day |
| Lightheaded when standing, or a near-faint | Possible low blood pressure | Sit down, then call your prescriber; your blood pressure medicine may need review |
| Shaky, sweaty or confused (if you take insulin or a sulfonylurea) | Possible low blood sugar | Treat as your diabetes plan says, then call |
| Peeing much less, dark urine, new confusion | Possible kidney injury from dehydration | Get seen the same day |
| Severe belly pain that won't stop, especially into the back | Possible pancreatitis or gallbladder problem | Get emergency care |
| Sudden vision loss or a new blind spot in one eye | Possible NAION | Call your doctor right away or go to urgent care |
| Swelling of the face, lips or throat, or trouble breathing | Serious allergic reaction | Call 911 |
| A fall, or new hip or groin pain | Possible fracture | Get seen promptly and tell them you take a GLP-1 |
Our guide on when to message your GLP-1 provider about side effects has more examples.
How to lower your GLP-1 risks after 65
Most GLP-1 risks for seniors can be lowered with the right checks before you start and closer watching during the first few months. Use this list with your clinician:
Before you start
- Bring a full list of medicines and supplements, including blood pressure pills, water pills, thyroid medicine, insulin or sulfonylureas, and anything taken on an empty stomach.
- Ask whether you need kidney blood work first, especially if you have kidney disease or take a water pill.
- If you have diabetes, ask how your other diabetes medicines will change.
- If you're 75 or older or have osteoporosis, ask about bone health and fall risk.
- If you have diabetic eye disease or a history of NAION, ask whether you need an eye exam first.
- Tell the prescriber about any planned surgery, colonoscopy or dental work.
During the first months
- Drink fluids through the day, even when you're not thirsty.
- Eat protein at every meal, even small meals.
- Keep moving and add strength exercises your clinician approves.
- Check your blood pressure at home if your clinician asks you to.
- Expect check-ins at each dose increase, and don't raise the dose faster than prescribed.
- Report weight loss that's faster than expected.
If you're still sorting out whether a GLP-1 fits, which medicine to ask about, or how you'd pay, our free Find My GLP-1 Path tool can help. It takes about 2 minutes, with 8 quick questions plus a state and age check, and no email is needed to see your match.
See which GLP-1 path fits youIf you decide to start: what a safer route looks like for seniors
For most older adults, the safer route is an FDA-approved GLP-1 prescribed by a clinician who reviews your full health history and medicine list and checks in at every dose change. That can be your own doctor, which is often the best first stop if you have several conditions, or a telehealth program that does the same review.
If you're on Medicare, check your plan first. Our guide to cash-pay GLP-1 options for seniors on Medicare explains how Medicare coverage works and where paying cash fits.
If you've already talked it over with your doctor and want an online option, Ro is one route that prescribes only FDA-approved GLP-1s. On Ro's pages we checked November 14, 2026:
- A Ro-affiliated provider reviews your online visit answers and, depending on your health review, may ask for a lab test.
- Ro's membership is $39 for the first month (refunded if you're not eligible), then $74 to $149 a month depending on the plan. Medicine is billed separately: the Wegovy pill and Foundayo pill start at $149 a month, the Wegovy pen at $199, and the Zepbound KwikPen at $299.
- Ro says people with Medicare, a Medicare supplement plan or TRICARE may still be eligible for certain cash-pay options through its membership, so plan on paying cash there rather than using Medicare. People with Medicaid aren't eligible for treatment on Ro.
Is your own doctor already on board, and do you want FDA-approved medicine with an online provider checking in?
See Ro's FDA-approved GLP-1 optionsOur guide to how Ro's GLP-1 program works walks through the steps.
FAQ
What are the biggest GLP-1 risks for seniors?
Dehydration that can lead to kidney injury, dizziness and fainting from low blood pressure, hip and pelvis fractures in people 75 and older, muscle loss, and eating too little. People who take insulin or a sulfonylurea also face a higher risk of low blood sugar.
Is there an age limit for GLP-1 medicines?
No. The Wegovy, Zepbound and Foundayo labels don't set an upper age limit. Your clinician decides based on your health, not your age, but very few people over 75 were in the trials.
Do GLP-1s cause falls in older adults?
The labels don't measure falls directly, but they report more low blood pressure and fainting on GLP-1s, especially in people taking blood pressure medicine. Wegovy's heart trial also found more hip and pelvis fractures in people 75 and older (2.4% vs 0.6%).
Is semaglutide or tirzepatide safer for seniors?
Neither is safer for everyone. Semaglutide (Wegovy) has more data in people 75 and older, including the fracture finding. Tirzepatide (Zepbound) has no kidney dose adjustment but was studied in very few people over 75. Your other conditions should drive the choice. See our best GLP-1 for seniors guide.
Do GLP-1s cause muscle loss in seniors?
Some lean mass loss is expected with any large weight loss. In body-scan studies, lean mass fell 9.7% on semaglutide and 10.9% on tirzepatide, while fat fell much more. Protein and strength training help protect muscle.
What's the new GLP-1 eye warning?
On November 9, 2026, the FDA said it is requiring all GLP-1 medicines to add a warning about NAION, a rare cause of sudden vision loss in one eye. If you notice sudden, painless vision loss, call your doctor right away.
Should I stop my GLP-1 before surgery?
Don't stop on your own. 2024 guidance from the American Society of Anesthesiologists and other groups says most people can keep taking it, while higher-risk patients may need a 24-hour liquid diet first. Tell your surgical team you take a GLP-1.
Can GLP-1s affect my other medicines?
Yes. GLP-1s slow the stomach, which can change how pills are absorbed. The semaglutide tablet raised levothyroxine levels 33% in a study, and the dose of insulin or sulfonylureas may need to drop.
Are compounded GLP-1s riskier for seniors?
They carry extra risks because they aren't FDA-approved or FDA-reviewed, and the FDA has received reports of dosing mistakes with compounded vials, some needing hospital care. Measuring doses with a syringe is harder with weaker eyesight or stiff hands.
Does Medicare cover GLP-1s for seniors?
It depends on why the medicine is prescribed and on your plan. Our guide for seniors on Medicare covers coverage and cash-pay options.
What we actually verified
| Claim | What we saw | Confidence |
|---|---|---|
| No upper age limit; no overall effectiveness difference after 65 | Wegovy (revised 06/2026), Zepbound (revised 08/2026) and Foundayo (revised 07/2026) labels, geriatric use sections, read November 14, 2026 | High |
| 75+ hip and pelvis fractures 2.4% vs 0.6% on Wegovy | Wegovy label, adverse reactions and geriatric use | High |
| Low blood pressure rates for Wegovy, Zepbound, Foundayo | Each medicine's label | High |
| Kidney injury rates and dehydration warning | Wegovy and Zepbound labels | High |
| Nausea, vomiting, diarrhea, constipation, dizziness rates | Wegovy label, Table 3 (2.4 mg injection) | High |
| Levothyroxine levels rose 33% with the semaglutide tablet | Wegovy label, drug interactions | High |
| Wegovy tablets: empty stomach, up to 4 ounces of water, 30-minute wait; Foundayo with or without food | Wegovy and Foundayo labels | High |
| FDA NAION warning for all GLP-1s, 6.4 vs 3.8 per 100,000 person-years | FDA Drug Safety Communication, November 9, 2026 | High |
| Lean mass down 9.7% (semaglutide) and 10.9% (tirzepatide) | STEP 1 and SURMOUNT-1 body-scan studies | High |
| Most patients can continue GLP-1s before surgery; 24-hour liquid diet for higher risk | ASA multi-society guidance, October 2024 | High |
| Compounded GLP-1 dosing errors and adverse event counts as of May 31, 2026 | FDA compounded GLP-1 concerns page | High |
| Ro: FDA-approved only; $39 then $74 to $149 membership; medicine from $149; Medicare, Medicare supplement and TRICARE members limited to cash-pay options; no Medicaid | Ro pricing, insurance and how-it-works pages, November 14, 2026 | High, prices may change |
Sources
Checked November 14, 2026 unless noted.
- Wegovy (semaglutide) injection and tablets prescribing information, revised 06/2026
- Zepbound (tirzepatide) prescribing information, revised 08/2026
- Foundayo (orforglipron) prescribing information, revised 07/2026
- FDA Drug Safety Communication: GLP-1 receptor agonists and NAION, November 9, 2026
- European Medicines Agency: PRAC concludes NAION is a very rare side effect of semaglutide, June 6, 2025
- FDA: concerns with unapproved GLP-1 drugs used for weight loss
- American Society of Anesthesiologists: multi-society GLP-1 guidance, October 2024
- Impact of semaglutide on body composition: STEP 1 exploratory analysis
- Body composition changes with tirzepatide in SURMOUNT-1
- Ro: weight loss pricing (ro.co/weight-loss/pricing)
- Ro: weight loss insurance and government plans FAQ (ro.co/weight-loss/insurance)
- Ro: how the weight loss program works (ro.co/weight-loss/how-it-works)
Still not sure which GLP-1 path fits you? Take our free Find My GLP-1 Path quiz — about 2 minutes, no signup.
Find My GLP-1 Path